RT Journal Article
SR Electronic
T1 Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on Down-regulation, CYP2C Induction and CYP2B6 Positive Control
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP dmd.116.074567
DO 10.1124/dmd.116.074567
A1 Niresh Hariparsad
A1 Diane Ramsden
A1 Jairam Palamanda
A1 Joshua G Dekeyser
A1 Odette A Fahmi
A1 Jane R Kenny
A1 Heidi Einolf
A1 Michael Mohutsky
A1 Magalie Pardon
A1 Amy Y Siu
A1 Liangfu Chen
A1 Michael Sinz
A1 Barry Jones
A1 Robert Walsky
A1 Shannon Dallas
A1 Suresh K Balani
A1 George Zhang
A1 David Buckley
A1 Donald Tweedie
YR 2017
UL http://dmd.aspetjournals.org/content/early/2017/06/20/dmd.116.074567.abstract
AB The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency and the Food and Drug Administration have issued guidances for the conduct of drug-drug interaction (DDI) studies. To examine the applicability of these regulatory recommendations specifically for induction, a group of scientists, under the auspices of the Drug Metabolism Leadership Group of the Innovation and Quality (IQ) Consortium, formed the Induction Working Group (WG). A team of 20 scientists, from 16 of the 39 pharmaceutical companies, which are members of the IQ Consortium, and three Contract Research Organizations, reviewed the recommendations, focusing initially on the current EMA guidance. Questions were collated from IQ member companies as to which aspects of the guidance required further evaluation. The EMA was then approached to provide insights into their recommendations on the following points; a) evaluation of down-regulation, b) in vitro assessment of CYP2C induction, c) the recommendation to use CITCO as the positive control for CYP2B6 induction, d) data interpretation (two-fold increase in mRNA as evidence of induction), and e) duration of incubation of hepatocytes with test article. The Induction WG conducted an anonymous survey among IQ member companies to query current practices, specifically focusing on how the aforementioned key points are evaluated. Responses were received from 19 companies. All data/information was blinded prior to being shared with the Induction WG. The results of the survey are presented together with consensus recommendations on down-regulation, CYP2C induction and CYP2B6 positive control. Data interpretation and incubation duration will be reported in subsequent manuscripts.